Markets
Halozyme Stock Plunges 12.90% After Earnings — Erasing $1.8 Billion Despite A Higher Outlook
The drug-delivery company raised its sales and adjusted earnings forecasts while quarterly revenue and net income climbed.
Halozyme Therapeutics (HALO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The drug-delivery company raised its sales and adjusted earnings forecasts while quarterly revenue and net income climbed.
Earnings
The drug-delivery company raised its earnings outlook and completed $400 million in buybacks; shares fell about 4% in Friday trading.
Earnings
CEO Helen Torley says Halozyme has not spoken to Merck, and the Dutch order covers eight markets that, with Germany, are about 20% of royalties.